This ASX health technology company could more than double in value: Broker

A major new recruit was a coup for this company.

ASX health technology company Blinklab Ltd (ASX: BB1) is entering an interesting phase, broker Morgans believes, with several share price catalysts soon to emerge.

A doctor appears shocked as he looks through binoculars on a blue background.

Image source: Getty Images

New technology opening up a large market

Blinklab produces smartphone software to diagnose conditions such as autism and ADHD. Morgans noted that readouts from four exploratory programs are soon to be published.

Blinklab has almost fully recruited participants for a pivotal study for autism, with Morgans saying this should be completed by the end of the year, with submission to the US Food and Drug Administration expected in the first quarter of calendar 2027.

Morgans added:

BB1's technology has broad applications across additional indications (adult autism, dementia detection, ketamine-based pharma intervention) and preliminary data is expected to read out over the next 12 months adding to the cadence of news flow. Recently, BB1's European ADHD study delivered positive results. A US pilot is due to start in 2QCY27, ahead of a pivotal study mirroring the autism path. We agree with management that this presents a significantly larger commercial opportunity than autism spectrum disorder.

The company also recently announced a major appointment, with Dr Raphael Bernier joining the board.

Dr Bernier was the former clinical lead for mental health at Apple Health. The company said he brought first-hand experience translating clinical science into digital products at a global scale.

Blinklab said at the time:

Dr Bernier brings a rare combination of clinical practice, internationally recognised research leadership and commercial product-development experience. His appointment is intended to deepen the Board's expertise as BlinkLab progresses its pivotal U.S. FDA 510(k) program for BlinkLab Dx1 and prepares for clinical adoption and commercialisation in the United States, subject to regulatory clearance. Dr Bernier recently retired from Apple Health, where he led the clinical development of the Mental Wellbeing app for iPhone, iPad and Apple Watch. He also conducted early-stage research across released and unreleased products in the Apple ecosystem and supported the rollout of additional products relating to child development and cognitive accessibility.

Morgans said there were significant market opportunities in the diagnosis of autism and ADHD, and Blinklab also had the opportunity to expand into other conditions.

Shares looking cheap

The broker has a 12-month price target of $1.76 on Blinklab shares compared to 66 cents currently.

If achieved, this would be a 166% return. The shares are well down from their 12-month high of $1.10.

Blinklab is valued at $114.6 million.

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Apple. The Motley Fool Australia has recommended Apple. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

a young boy dressed in a business suit and wearing thick black glasses peers straight ahead while sitting at a heavy wooden desk with an old-fashioned calculator and adding machine while holding a pen over a large ledger book.
Broker Notes

Is the Xero share price too cheap to ignore?

If the company's growth plans stack up, this share could be one to watch.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Man putting coins in a wooden piggy bank next to piles of coins.
Broker Notes

Are NAB shares cheap or expensive? Brokers can't agree

The experts have their say after this week's profit report.

Read more »

Happy investor on tablet with finance graphs rising in overlay.
Broker Notes

Could Goodman and Paladin Energy shares rise 20% to 80%?

Let's see why these shares are being tipped to charge higher from current levels.

Read more »

Close-up of a business man's hand stacking gold coins into piles on a desktop.
Broker Notes

Clime Capital pays an 8.7% dividend yield. Pitt Street Partners says it's undervalued

A combination of dividends and capital gains could make this share one to watch.

Read more »

A man in a suit looks surprised as he looks through binoculars.
Broker Notes

These 3 ASX shares are on my watchlist for 2027

I've been on the hunt for value on the ASX.

Read more »

Piles of coins with rising arrows.
Broker Notes

I screened the ASX for five companies rated a strong buy by brokers

These companies could offer strong share price upside.

Read more »

Three small children reach up to hold a toy rocket high above their heads in a green field with a blue sky above them.
Broker Notes

2 ASX shares tipped by brokers to climb 110% or higher over the next 12 months

Brokers think these ASX shares could storm higher over the next 12 months.

Read more »